Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 +2.63 (+0.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

68 69 Next >

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts ↗

September 25, 2025

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Via Benzinga

Vertex Announces Key Advancements Across Kidney Portfolio

September 25, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

My 3 Favorite Stocks to Buy Right Now ↗

September 25, 2025

Uncertainty is in the air. But these stocks inspire confidence.

Via The Motley Fool

Topics Artificial Intelligence Economy

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top GARP Stock ↗

September 24, 2025

Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation.

Via Chartmill

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

September 23, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

September 22, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex...

Via StockStory

Topics Artificial Intelligence

Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon ↗

September 20, 2025

There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels.

Via The Motley Fool

Topics Government Intellectual Property World Trade

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

September 18, 2025

From Vertex Pharmaceuticals

Via Business Wire

2 Growth Stocks to Buy and Hold Forever ↗

September 17, 2025

Look beyond the recent headwinds these two have faced.

Via The Motley Fool

Topics World Trade

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Screens as a Top Undervalued Stock with Strong Fundamentals ↗

September 17, 2025

Vertex Pharmaceuticals (VRTX) is a strong value stock with high profitability, zero debt, and solid growth, trading at an attractive valuation within the biotech sector.

Via Chartmill

Why This Biotech Company Could Be a Growth Stock Powerhouse ↗

September 17, 2025

The stock has soared in the triple-digits over the past decade.

Via The Motley Fool

1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals ↗

September 15, 2025

Here's why you can't find a Wall Street analyst who will tell you to sell this stock.

Via The Motley Fool

Topics Intellectual Property

3 Absurdly Cheap Stocks to Buy for the Long Haul ↗

September 12, 2025

They trade at some incredibly low earnings multiples.

Via The Motley Fool

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years ↗

September 11, 2025

Via Benzinga

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

September 11, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Technical Breakout Potential ↗

September 11, 2025

Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors.

Via Chartmill

Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% ↗

September 11, 2025

These companies are reaching key milestones.

Via The Motley Fool

1 Safe-and-Steady Stock to Research Further and 2 We Turn Down

September 11, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Why This Biotech Company Could Be a Growth Stock Powerhouse ↗

September 04, 2025

Recent developments aren't as devastating to the company's prospects as some might think.

Via The Motley Fool

Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews ↗

September 03, 2025

Via Benzinga

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Top GARP Stock with Strong Growth and Reasonable Valuation ↗

September 03, 2025

Vertex Pharmaceuticals (VRTX) exemplifies the GARP strategy with strong growth, a reasonable valuation, high profitability, and a robust debt-free balance sheet.

Via Chartmill

Tuesday's session: top gainers and losers in the S&P500 index ↗

September 02, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Via Chartmill

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗

September 02, 2025

Via Benzinga

3 No-Brainer Stocks to Buy Right Now ↗

August 31, 2025

Investing in these pharmaceutical stocks is an easy decision.

Via The Motley Fool

Topics World Trade

My 2 Favorite Stocks to Buy Right Now ↗

August 31, 2025

Looking for good investing ideas? These two stocks could be huge winners for long-term investors.

Via The Motley Fool

Topics Artificial Intelligence

Navigating the Currents: Top Sectors Primed for Growth in Q3 2025

August 27, 2025

The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,...

Via MarketMinute

Topics Artificial Intelligence Economy Retirement

What's Driving the Market Sentiment Around Vertex Pharmaceuticals? ↗

August 27, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vertex Pharmaceuticals (NQ:VRTX)

All News about Vertex Pharmaceuticals

Starting at $3.75/week.

Subscribe Today